Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

15.19
+0.19001.27%
Post-market: 15.10-0.0900-0.59%17:21 EDT
Volume:3.57M
Turnover:54.03M
Market Cap:2.10B
PE:-4.21
High:15.43
Open:15.10
Low:14.76
Close:15.00
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:1.31
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:24.80
PE(LYR):-4.93

Loading ...

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

THOMSON REUTERS
·
Apr 19

Compass Pathways Plc - Already Working With FDA on Rolling Submission for Comp360 in Treatment-Resistant Depression

THOMSON REUTERS
·
Apr 19

BUZZ-Psychedelic drug developers rise after CBS report Trump backs more research

Reuters
·
Apr 17

Compass Pathways publishes 2025 annual report

Reuters
·
Apr 16

Compass Pathways announces annual shareholder meeting

Reuters
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Bloom Energy, BlackRock, CoreWeave

Reuters
·
Apr 14

BUZZ-Compass Pathways rises as it launches US training grants for psilocybin care

Reuters
·
Apr 14

Compass Pathways Announces U.s Grant Program for the Creation of Post-Approval Comp360 Provider Training

THOMSON REUTERS
·
Apr 14

Compass Pathways to present at Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 08

Compass Pathways grants 173,320 inducement equity awards to new hires under 2026 plan

Reuters
·
Apr 08

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 08

LifeSci Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)

TIPRANKS
·
Mar 28

Compass Pathways Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 26

RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

TIPRANKS
·
Mar 26

Compass Pathways price target lowered to $18 from $20 at Canaccord

TIPRANKS
·
Mar 26

Compass Pathways Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 26

Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Mar 26

COMPASS Pathways (CMPS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Mar 25